HVIVO (HVO:AIM) 28.2pMarket cap: £191.9 millionFluCamp does not sound like much fun for volunteers, but for leading CRO (contract research organisation) HVIVO (HVO:AIM) it represents a flagship service which is attracting growing interest from big pharma and biotechnology companies.The company is at the forefront of HCTs (human challenge trials), a fast-growing niche within the large CRO...

Wetherspoon chair sells 1% of companyCreightons and hVIVO executives sell upAssetco director adds to holdingTim Martin, chairman of pub group JD Wetherspoon (JDW), sold 1,361,000 shares at 739p each for a total value of more than £10 million on 29 July.As a result of the deal, Martin's voting rights now comprise of 30,382,253 shares, equivalent to 24.6% of the issued share capital of the...

hVIVO directors sell shares ?to meet demand?Greencore director buys £50,000 sharesCathal Friel, co-founder and chairman of infectious and respiratory diseases company hVIVO (HVO:AIM), sold 25,937,909 shares at 28p for a total value of £7,262,615 on 14 February.Brendan Buckley, non-executive of the company, sold 4,017,269 also at 28p for a total value of £1,124,835 on the same day.Therefore...

Neil Woodford, one of Britain's best known fund managers, has taken the opportunity to top-up holdings across a number of innovative businesses in recent weeks.A quick screen of the regulatory news service (RNS) reveals buying by Woodford Investment Management, the manager behind the CF Woodford Equity Income Fund (GB00BLRZQ513) and the early-growth focused Woodford Patient Capital Trust...